Anabolic and anticatabolic agents in critical care

Mile Stanojcic; Celeste C. Finnerty; Marc G. Jeschke

doi:10.1097/MCC.0000000000000330

Anabolic and anticatabolic agents in critical care

Mile Stanojcic, Celeste C. Finnerty, Marc G. Jeschke

Surgery

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.

Original language	English (US)
Pages (from-to)	325-331
Number of pages	7
Journal	Current Opinion in Critical Care
Volume	22
Issue number	4
DOIs	https://doi.org/10.1097/MCC.0000000000000330
State	Published - Aug 1 2016

Keywords

anabolic
anticatabolic
burns
critical illness
hypermetabolism
insulin
metformin
oxandrolone
propranolol

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine

Access to Document

10.1097/MCC.0000000000000330

Cite this

@article{5db633cd632041fe9408006d5806c3ef,

title = "Anabolic and anticatabolic agents in critical care",

abstract = "Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.",

keywords = "anabolic, anticatabolic, burns, critical illness, hypermetabolism, insulin, metformin, oxandrolone, propranolol",

author = "Mile Stanojcic and Finnerty, {Celeste C.} and Jeschke, {Marc G.}",

year = "2016",

month = aug,

day = "1",

doi = "10.1097/MCC.0000000000000330",

language = "English (US)",

volume = "22",

pages = "325--331",

journal = "Current Opinion in Critical Care",

issn = "1070-5295",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Anabolic and anticatabolic agents in critical care

AU - Stanojcic, Mile

AU - Finnerty, Celeste C.

AU - Jeschke, Marc G.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.

AB - Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.

KW - anabolic

KW - anticatabolic

KW - burns

KW - critical illness

KW - hypermetabolism

KW - insulin

KW - metformin

KW - oxandrolone

KW - propranolol

UR - http://www.scopus.com/inward/record.url?scp=84973392560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973392560&partnerID=8YFLogxK

U2 - 10.1097/MCC.0000000000000330

DO - 10.1097/MCC.0000000000000330

M3 - Review article

C2 - 27272101

AN - SCOPUS:84973392560

SN - 1070-5295

VL - 22

SP - 325

EP - 331

JO - Current Opinion in Critical Care

JF - Current Opinion in Critical Care

IS - 4

ER -

Anabolic and anticatabolic agents in critical care

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this